Gufic Biosciences Limited (BOM:509079)
India · Delayed Price · Currency is INR 314.00
0.00 (0.00%)
At close: Feb 12, 2026
Gufic Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 8,736 | 8,198 | 8,067 | 6,906 | 7,792 | 4,877 | |
Revenue Growth (YoY) | 8.69% | 1.63% | 16.80% | -11.36% | 59.76% | 28.74% |
Cost of Revenue | 3,963 | 3,820 | 3,986 | 3,393 | 4,207 | 2,565 |
Gross Profit | 4,773 | 4,378 | 4,080 | 3,513 | 3,585 | 2,312 |
Selling, General & Admin | 1,466 | 1,307 | 1,133 | 940.25 | 913.47 | 691.2 |
Other Operating Expenses | 1,955 | 1,688 | 1,452 | 1,197 | 1,191 | 781.26 |
Operating Expenses | 3,701 | 3,205 | 2,755 | 2,360 | 2,294 | 1,635 |
Operating Income | 1,072 | 1,173 | 1,326 | 1,153 | 1,291 | 676.53 |
Interest Expense | -320.44 | -230.28 | -147.58 | -66.36 | -40.06 | -117.66 |
Interest & Investment Income | 15.74 | 15.74 | 14.13 | 14.13 | 18.8 | 14.51 |
Currency Exchange Gain (Loss) | -22.97 | -22.97 | 4.97 | -29.61 | 6.93 | 14.34 |
Other Non Operating Income (Expenses) | 21.19 | 4.46 | -17.63 | -4.56 | -8.97 | -10.77 |
EBT Excluding Unusual Items | 765.48 | 940.28 | 1,180 | 1,067 | 1,268 | 576.95 |
Impairment of Goodwill | - | - | - | - | - | -0.21 |
Gain (Loss) on Sale of Assets | 1.16 | 1.16 | -23 | 0.3 | 0.68 | 0.37 |
Pretax Income | 766.64 | 941.44 | 1,157 | 1,067 | 1,268 | 577.12 |
Income Tax Expense | 197.46 | 244.95 | 295.36 | 270.16 | 309.98 | 134.8 |
Earnings From Continuing Operations | 569.18 | 696.49 | 861.36 | 797.05 | 958.4 | 442.32 |
Minority Interest in Earnings | 0.02 | 0.01 | - | - | - | - |
Net Income | 569.19 | 696.5 | 861.36 | 797.05 | 958.4 | 442.32 |
Net Income to Common | 569.19 | 696.5 | 861.36 | 797.05 | 958.4 | 442.32 |
Net Income Growth | -32.98% | -19.14% | 8.07% | -16.84% | 116.68% | 94.96% |
Shares Outstanding (Basic) | 100 | 100 | 99 | 97 | 97 | 97 |
Shares Outstanding (Diluted) | 100 | 100 | 99 | 97 | 97 | 97 |
Shares Change (YoY) | 0.11% | 1.78% | 1.63% | - | - | 24.56% |
EPS (Basic) | 5.68 | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 |
EPS (Diluted) | 5.68 | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 |
EPS Growth | -33.03% | -20.53% | 6.33% | -16.85% | 116.80% | 56.43% |
Free Cash Flow | 419.75 | 470.42 | -1,202 | -2,142 | 187.86 | 748.52 |
Free Cash Flow Per Share | 4.18 | 4.69 | -12.20 | -22.09 | 1.94 | 7.72 |
Dividend Per Share | - | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 |
Dividend Growth | - | - | - | - | - | 100.00% |
Gross Margin | 54.63% | 53.41% | 50.58% | 50.87% | 46.01% | 47.40% |
Operating Margin | 12.27% | 14.31% | 16.44% | 16.70% | 16.57% | 13.87% |
Profit Margin | 6.52% | 8.50% | 10.68% | 11.54% | 12.30% | 9.07% |
Free Cash Flow Margin | 4.81% | 5.74% | -14.89% | -31.01% | 2.41% | 15.35% |
EBITDA | 1,277 | 1,310 | 1,422 | 1,307 | 1,430 | 803.85 |
EBITDA Margin | 14.62% | 15.98% | 17.63% | 18.92% | 18.36% | 16.48% |
D&A For EBITDA | 205.34 | 136.45 | 96.33 | 153.43 | 139.3 | 127.32 |
EBIT | 1,072 | 1,173 | 1,326 | 1,153 | 1,291 | 676.53 |
EBIT Margin | 12.27% | 14.31% | 16.44% | 16.70% | 16.57% | 13.87% |
Effective Tax Rate | 25.76% | 26.02% | 25.53% | 25.31% | 24.44% | 23.36% |
Revenue as Reported | 8,789 | 8,234 | 8,088 | 6,932 | 7,823 | 4,914 |
Advertising Expenses | - | 18.63 | 21.23 | 59.56 | 33.44 | 18.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.